Skip to content

Three Quick Facts: Spire Healthcare, Nightcap and Immupharma

Three Quick Facts: Spire Healthcare, Nightcap and Immupharma

Here are three things you need to know in the financial markets this morning from investment writer, Tony Cross.

#1. Spire Healthcare signs another NHS support deal

Spire Healthcare LON:SPI has this morning announced that along with other private healthcare providers, it has reached an agreement in principal to support NHS England through the current COVID pandemic. The arrangement runs to the end of March and will be similar to a deal agreed in December 2020. This is likely to prove useful for the company, both when it comes to short term capital support and also in the longer term as it will have the potential to lead to higher demand once the impact of this wave of the pandemic is behind us.


#2. Nightcap investors will be raising a glass

Bar operator Nightcap LON:NGHT published a trading update this morning covering the 26 weeks to 26th December. Like for like sales were up by almost a quarter from the same period pre-pandemic, whilst once new bar openings are accounted for, that figure jumped to more than 46%. Stripping out the last two weeks of the reporting period – when “Plan B” Covid measures were in effect – offered an even more upbeat assessment of sales. The company is approaching one year since its IPO, has £9.4m cash at the bank and expects to see further estate expansion in the coming months.

#3. Immupharma notifies over stake

Pioneering drug developer Immupharma LON:IMM has published a TR-1 this morning advising that Alora Pharmaceuticals of Georgia, USA, has seen its stake in the company exceed 3%. The threshold was crossed just before Christmas so was likely triggered by the participation of Alora – a longstanding partner of the business – in December’s placing, which was undertaken at an 80% premium to the share price at the time.

Share this article

Invest with these platforms

Hargreaves Lansdown

IG

Interactive Brokers

Interactive Investor

Charles Stanley

IG

Interactive Brokers

Charles Stanley

Looking for great investing ideas? Get our free newsletter.

This article does not constitute investment advice.  Do your own research or consult a professional advisor.

Learn with our free 'How to' Guides

Our latest in-depth company reports

On the podcast

Sign up for great investing stock tips

Thanks to our Site Partners

Our partners are established, regulated businesses and we are grateful for their support.

Aquis
CME Group
FP Markets
Pepperstone
Schroders

aberdeen
WisdomTree
ARK
Plus500
CMC Markets
Back To Top